Fundraising Fox
/Companies
Sign in

Attomarker Seed

2 known investors

Find your way into Attomarker Seed

Each arrow is one introduction. Sign up to fill in the first one.

566 people can intro you to Andrew

Ask Victoria Fäh to introduce you to Andrew Shaw

You →Victoria · together at University of Exeter →Andrew

Sign up to find every way you can get introduced to Attomarker Seed

  • Your email: who you already know at Attomarker Seed, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Attomarker Seed team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Attomarker develops a multiplexed blood testing platform that measures multiple biomarkers simultaneously and quantitatively, using gold particle nanotechnology, microfluidics and data analytics. Its tests, including a COVID Antibody Spectrum Test that classifies Long COVID immune endotypes, serve patients, clinicians, researchers and clinical partners for precision diagnostics and personalised medicine.

Deep TechDigital HealthMedical Devices

Founders & leadership

ASAndrew Shaw
Andrew ShawCEO and FounderAndrew Shaw studied quantum mechanics and spent two years at Stanford before founding EvanesCo, a company focused on counter-terrorism and weapons detection; he later sold a rheumatoid arthritis company and went on to develop biomarker detection technology as a research grant recipient at the University of Exeter, which became the core intellectual property for Attomarker.

Investors · 2

Milltrust International GroupreportedLondon · $2.5M

How we know: the VCSheet dataset · Not right? Tell us

Frequently asked questions

What does Attomarker Seed do?
Attomarker develops a multiplexed blood testing platform that measures multiple biomarkers simultaneously and quantitatively, using gold particle nanotechnology, microfluidics and data analytics. Its tests, including a COVID Antibody Spectrum Test that classifies Long COVID immune endotypes, serve patients, clinicians, researchers and clinical partners for precision diagnostics and personalised medicine.
Who founded Attomarker Seed?
Attomarker Seed was founded by Andrew Shaw.
Who are Attomarker Seed's investors?
Attomarker Seed's investors include Future Planet Capital, Milltrust International Group.